Skip to main content

Table 1 H3K27me3 and EZH2 IHC expression in melanoma metastases prior to anti-PD-1 inhibition

From: H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade

  H3K27me3+H3K27me3−p valueEZH2+EZH2−p value
 n (%)n (%)n (%) n (%)n (%) 
Number4429 (65.9)15 (34.1) 6 (13.6)38 (86.4) 
Gender
 Female15 (34.1)9 (60.0)6 (40.0)p = .5520 (0)15 (100)p = .058
 Male29 (65.9)20 (69.0)9 (31.0) 6 (20.7)23 (79.3) 
Location of metastases
 Local tumor recurrence5 (11.4)4 (80.0)1 (20.0) 0 (0)5 (100) 
 Cutaneous metastases16 (36.4)11 (69.0)5 (31.0) 2 (12.5)14 (87.5) 
 Lymph node metastases13 (29.5)7 (53.8)6 (46.2)p = .3672 (15.4)11 (84.6)p = .433
 Lung metastases5 (11.4)2 (40.0)3 (60.0) 0 (0)5 (100) 
 Brain metastases3 (6.8)3 (100)0 (0) 1 (33.3)2 (66.6) 
 Abdominal metastases2 (4.5)2 (100)0 (0) 1 (50.0)1 (50.0) 
Response to anti-PD-1 blockade
 Non-responder20 (45.5)13 (65.0)7 (35.0)p = .9302 (10.0)18 (90.0)p = .685
 Responder24 (54.5)16 (66.7)8 (33.3) 4 (16.7)20 (83.3) 
Tumor-infiltrating lymphocytes
 Absent35 (79.5)25 (71.4)10 (28.6)p = .1415 (14.3)30 (85.7)p > .999
 Non-brisk7 (15.9)4 (57.1)3 (42.9) 1 (14.3)6 (85.7) 
 Brisk2 (4.5)0 (0)2 (100) 0 (0)2 (100) 
  1. Samples were analyzed for patient’s gender, the location of metastases and patients response to anti-PD-1 blockade. Tumor-infiltrating lymphocytes were assessed using the scoring system by Clark. Significance was determined by Χ2 test for categorical data. In cases of expected frequencies < 5, Fisher’s exact test was applied